Though still very early stage, initial Phase II results testing Biolinerx Ltd.’s CXCR4 antagonist, BL-8040, in relapsed and refractory acute myeloid leukemia (AML) patients caught the attention of Wall Street Monday, sending shares of the Jerusalem-based firm jumping 15 percent.